Literature DB >> 25111095

Biologics in systemic lupus erythematosus: current options and future perspectives.

Md Yuzaiful Md Yusof1, Edward M Vital, Paul Emery.   

Abstract

Data from clinical trials highlighted the potential and pitfalls of the use of biologics to treat systemic lupus erythematosus. With improved understanding of immunopathogenesis and lessons learned from controlled trials, there is a growing optimism for personalized treatment from an increasing range of targeted therapies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25111095     DOI： 10.12968/hmed.2014.75.8.440

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


  3 in total

1.  Transforming growth factor-β-activated kinase 1 resistance limits glucocorticoid responsiveness to Toll-like receptor 4-mediated inflammation.

Authors:  Fansheng Kong; Gloria Laryea; Zhiwei Liu; Sandip Bhattacharyya
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

2.  B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus.

Authors:  Yasser M El-Sherbiny; Md Yuzaiful Md Yusof; Antonios Psarras; Elizabeth M A Hensor; Kumba Z Kabba; Katherine Dutton; Alaa A A Mohamed; Dirk Elewaut; Dennis McGonagle; Reuben Tooze; Gina Doody; Miriam Wittmann; Paul Emery; Edward M Vital
Journal:  Arthritis Rheumatol       Date:  2020-04-03       Impact factor: 15.483

3.  Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.

Authors:  Sabih Ul Hassan; Md Yuzaiful Md Yusof; Paul Emery; Shouvik Dass; Edward M Vital
Journal:  Front Med (Lausanne)       Date:  2020-08-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.